Nuria Kotecki

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár et al. · JAMA Oncology · 2018 · 310 citations · Full text

Medicine, Oncology, Pharmacology +17

A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer

Émilie Le Rhun, Sophie Taillibert, Fahed Zaïri et al. · Journal of Neuro-Oncology · 2013 · 118 citations

Medicine, Oncology, Surgery +15

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Ulka N. Vaishampayan, Patrick Schöffski, Alain Ravaud et al. · Journal for ImmunoTherapy of Cancer · 2019 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy

Maria Alice Franzoi, Daniel Eiger, Lieveke Ameye et al. · JNCI Journal of the National Cancer Institute · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17